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Summary 
Activated mouse peritoneal macrophages produce nitric oxide (NO) via a nitric oxide synthase 
that is inducible by interferon 3, (IFN-7): iNOS. We have studied the mechanisms by which 
transforming growth factor ~1 (TGF-~) suppresses IFN-7-stimulated NO production. TGF-~/ 
treatment reduced iNOS specific activity and iNOS protein in both cytosolic and particulate 
fractions as assessed by Western blot with monospecific anti-iNOS immunoglobulin G. TGF-~ 
reduced iNOS mRNA without affecting the transcription ofiNOS by decreasing iNOS mRNA 
stability. Even after iNOS was already expressed, TGF-~ reduced the amount of iNOS protein. 
This was due to reduction ofiNOS mRNA translation and increased degradation ofiNOS protein. 
The potency of TGF-B as a deactivator of NO production (50% inhibitory concentration, 5.6 
_+ 2 pM) may reflect its ability to suppress iNOS expression by three distinct mechanisms: decreased 
stability and translation of iNOS mRNA, and increased degradation of iNOS protein. This is 
the first evidence that iNOS is subject  to other than transcriptional regulation. 
ecent appreciation of the role of endogenously gener- 
ated nitric oxide (NO) 2 in the physiology and patho- 
physiology of every organ system raises interest in mecha- 
nisms by which NO production may be regulated (1). This 
question assumes additional significance in view of the ability 
of NO to kill or damage cells (2). 
Constitutive isoforms of NO synthase (chiOS) are expressed 
in neurons and endothelium. These enzymes produce small 
amounts of NO over several minutes in response to agonists 
that elevate intracellular Ca  2  + (1). Other cell types (macro- 
phages [3], tumor cells [4], hepatocytes [5, 6], mesangial cells 
[7], endothelial cells [8], smooth muscle cells [9], cardiac myo- 
cytes [10-12],  glial cells [13, 14], and keratinocytes [15]) ex- 
press  an inducible isoform of NO  synthase (iNOS)  that 
produces relatively large amounts of NO over many hours 
without dependence on secretagogues.  Nothing is known 
to regulate iNOS after it has been induced (1). 
Suppression of iNOS expression was first shown in mac- 
rophages exposed to TGF-B (16). These results were confirmed 
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synthase; NADPH, 3-nicotinamide-adenine dinucleotide phosphate; NO, 
nitric oxide. 
(17) and extended in mesangial cells (18), smooth muscle cells 
(19, 20),  and cardiac myocytes (11). Subsequently,  suppres- 
sion of iNOS expression was observed with epidermal growth 
factor (EGF)-treated keratinocytes (15), phtelet-derived growth 
factor (PDGF)-treated smooth muscle cells (19), IL-8-treated 
nentrophils (21), and IL-4-treated macrophages (22). In no 
case has the mechanism of suppression been analyzed. 
The iNOS from the mouse macrophage-like cell line RAW 
264.7 has been purified (23, 24) and cloned (25-27), and a 
monospedfic antiserum to it raised (26), allowing us to study 
TGF-3-mediated suppression of NO production in macro- 
phages at the molecular level. 
Materials and Methods 
Reagents,  Nitroblue tetrazolium (NBT), 5-bromo-4-chloro-3- 
indolyl phosphate (BCIP), /3-nicotinamide-adenine  dinucleotide 
phosphate (reduced;  NADPH), ravin adenine  dinudeotide (FAD), 
and protease inhibitors were obtained from Sigma Chemical Co. 
(St. Louis, MO).  Tetrahydrobiopterin was from Dr. B. Schirks 
Laboratories (Jona, Switzerland).  Dithiothreitol was from GIBCO- 
BRL (Gaithersburg, MD). Recombinant mouse IFN-3" (protein 
concentration, 1.1 mg/ml; sp act, 5.2 x  106 U/rag; LPS content, 
<10 pg/ml) was kindly provided by Genentech (South San Fran- 
cisco, CA). Recombinant human TGF-B1 (hereafter referred to as 
TGF-B) was a kind gift from Amgen (Thousand  Oaks, CA). Rabbit 
anti-mouse iNOS IgG was raised against iNOS purified from the 
RAW 264.7 cell line (26). Mouse/3-actin  oligonucleotide  and mouse 
glyceraldehyde-3-phosphate  dehydrogenase  (GAPDH) cDNA were 
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taining  the mouse fl-actin  eDNA was  a kind gift of Drs.  M. 
Prystowsky and A. Orlofsky (University of Pennsylvania, Philadel- 
phia, PA). All chemicals were of reagent or electrophoresis grade. 
Cells Culture and Lysis.  Female  CD-1 mice, 8-12 wk old (Charles 
River Breeding Laboratories, Wilmington, MA), were injected in- 
traperitoneally  with 4% Brewer's  thioglycollate  broth 03~co Labora- 
tories, Detroit, MI). 4 d after injection, peritoneal macrophages 
were harvested and processed as described (28). Macrophages made 
up 86 +_  9% of the total cell population by morphologic criteria 
(67 experiments). Cells were seeded  either in 24-well  plates (Costar, 
Cambridge,  MA)  or in  100-mm-diameter tissue culture  dishes 
(Coming, Coming, NY) at 2  x  los cells/ml in RPMI 1640 (JRH 
Biosciences, Lenexa,  KS) with 10% heat-inactivated  FCS (HyClone 
Laboratories,  Logan, UT). IFN-~ was added  with or without TGF-fl 
at the indicated concentrations. The cells were incubated at 37~ 
5% CO2 in humidified air. An aliquot of the conditioned medium 
was  removed for assay of NO2-  content  (see below).  Where 
noted, monolayers  were washed in warm PBS and scraped  into cold 
PBS. The ceils were centrifuged at 500 g for 15 rain at 4~  The 
ceil pellet was frozen at - 70~  for later processing or resuspended 
in 500 #1 of sonication buffer (100 mM sodium phosphate, pH 7.4, 
25  mM  NaC1, containing  5  #g/ml  pepstatin  A,  1  #g/ml 
chymostatin, 5 #g/ml aprotinin,  100/~M PMSF). The cell pellet 
was sonicated using a Sonifier 250 (Branson Ultrasonics Co., Dan- 
bury, CT), as follows: 50% duty cycle, 10 s each at intensities of 
1, 2, and 3. An aliquot of the whole lysate was reserved at - 70~ 
Where noted, the remaining lysate was centrifuged at 100,000 g 
for 30 min at 4~  in order to separate cytosol and particulate frac- 
tions in a modification of the procedure of Pollock et al. (29). The 
cytosol was stored as for the lysate. The pellet was resuspended 
in buffer A (sonication buffer containing 1 M KC1) and centrifuged 
at  100,000 g for 30 min at 4~  The pellet was resuspended in 
0.2 mM 3-([3-cholamidopropyl]dimethylammonio)-l-propanesul- 
fonate in sonication buffer and kept on ice for 20 rain, with peri- 
odic resuspension. An aliquot of this suspension was used for pro- 
tein assay, and the remainder stored at  -70*C. 
SDS-PAGE and Western Blot.  SDS-PAGE  was carried out ac- 
cording to the method of Laemmli (30) with prestained molecular 
weight markers (Betbesda Research Laboratories, Gaithersburg, 
ME)). After completion of SDS-PAGE, proteins were transferred 
onto 0.2-#m pore-size nitrocellulose membranes (Schleicber & 
Schuell, Inc., Keene, NH) using 20% methanol, 25 mM Tris, 192 
mM glycine, pH 8.3. The membrane was blocked for 1 h at room 
temperature with 1% BSA in Tris-buffered saline (TBS; 25 mM 
Tris, pH 7.5, 150 mM NaC1, 0.02% NAN3) +  0.2% Tween 20. 
The membrane was then washed once in TBS and incubated with 
rabbit anti-mouse  iNOS IgG used at 1:2,000 or 1:3,000 dilution 
for 2-4 h. After washing, the membrane was incubated for 45 min 
with a 1:10,000 dilution of donkey anti-rabbit  IgG, F(ab')2 con- 
jugated to alkaline phosphatase (Jackson Immunoresearch Labora- 
tories, West Grove, PA). After washing, the membrane was equili- 
brated in alkaline phosphatase buffer (100 mM Tris, pH 9.5, 100 
mM NaC1, 5 mM MgClz) and developed in  a solution  of 16 
#g/ml NBT and 167 #g/ml BCIP in alkaline phosphatase buffer. 
Metabolic Labeling and Immunoprecipitation.  8  x  106 peritoneal 
cells were seeded in 4 ml of ILPMI 1640 +  10% FCS in 60-mm- 
diameter  tissue culture  dishes (Coming).  After  adherence and 
washing as described above, the macrophages were stimulated with 
20 ng/ml IFN-7 for 16-18 h. TGF-fl (2.5 ng/ml) or medium was 
then added for the indicated times. The medium was aspirated and 
replaced with pulse medium (KPMI 1640 without t-cysteine [ICN 
Biomedicals, Costa Mesa, CA], containing 10 mM Hepes, pH 7.4). 
The macrophages were incubated at 37~  5% COs for 45 min 
in order  to deplete cellular stores of t-cysteine.  [3SS]L-Cysteine 
(1,220 Ci/mmol,  300  #Ci/dish  [Amersham  Corp.,  Arlington 
Heights, IL]) in pulse medium was added for 30 rain. The medium 
was removed, the dishes were washed three times in warm PBS, 
and the cells were scraped into cold PBS. After centrifugation  at 
500g for 15 rain, the cell pellet was frozen at -70oc until further 
processed. The cell pellet was lysed in 150 mM NaC1, 10 mM Tris, 
pH  8.0,  1%  Triton  X-100,  5  #g/ml  pepstatin  A,  1  #g/ml 
chymostatin, 5/xg/ml aprotinin, 100 #M PMSF. The protein con- 
tent of the lysate was determined by Bradford protein assay. Equal 
amounts of protein from each lysate (20-80 #g) were precleared 
overnight with protein A-Sepharose beads (Sigma Chemical Co.) 
at 4~  These  samples were then incubated  overnight  with  1 
#l/sample of anti-iNOS antiserum or preimmune serum at 4~ 
The antigen-antibody solution was then incubated with protein 
A-Sepharose beads for 1.5 h, washed, and the immunoprecipitated 
sample eluted from the beads using 4 x  Laemmli reducing buffer. 
The samples were subjected to SDS-PAGE as described above. The 
gel was fixed (30% methanol,  7% acetic acid, 1 h), treated with 
ENTENSIFY hydrofluor (New England Nuclear, Boston, MA) as 
directed by the manufacturer, dried,  and subjected to autoradi- 
ography. 
Pulse-Chase Analysis.  Macrophage monolayers were prepared 
as in the section above and stimulated with 20 ng/ml IFN-'y for 
16-18 h. TGF-fl (2.5 ng/ml) or medium was then added for a fur- 
ther 45 rain. The medium was aspirated and replaced with pulse 
medium; TGF-B diluted in pulse medium was added back to the 
appropriate dishes. The cells were starved of t-cysteine and pulsed 
with  [3ss]t-cysteine as described above for 3 h.  Chase medium 
(pulse medium containing  15 mg/liter cold t-cysteine) was then 
added for the indicated times. At the conclusion of the chase, the 
ceils were processed as above  for immunoprecipitation, SDS-PAGE, 
and autoradiography. 
NOe- Accumulation.  NO2-  accumulation was used as an in- 
dicator of NO production in the medium and was assayed by the 
Griess reaction (16). 100 #1 Griess reagent was added to 100 #1 
of each supematant  in triplicate. The plates were read using an 
ELISA plate reader (MR5000; Dynatech,  Chantilly, VA) at 550 
nm against a standard curve of NaNO2. 
NOS Enzyme Assay.  NOS activity was measured as described 
(23) in 20 mM Tris-HC1, pH 7.9, containing 4 #M FAD, 4 #M 
tetrahydrobiopterin,  3  mM  dithiothreitol,  and  2 mM  each of 
L-arginine and NADPH. The reaction was carried out in duplicate 
for 120 or 180 min at 37~  in 100 #1 in 96-well plates (Coming). 
Residual NADPH was oxidized enzymatically as previously de- 
scribed (23), and the Griess assay was performed as above. As a 
control for turbidity or other interference with the assay, an addi- 
tional well for each sample contained all reagents except t-arginine 
and NADPH, for which water was substituted.  The absorbance 
value from this well (typically 0.05-0.1) was subtracted from that 
of the mean of the test wells. 
DNA and Oligonucleotide Probes.  DNA probes were random 
primer labeled with [32p]dCTP according to standard protocols 
(31). Oligonucleotide probes were 5' end radiolabeled  with T4 poly- 
nucleotide kinase (Stratagene, La Jolla, CA) in the presence of 50 
mCi of ot-[32p]ATP (~6,000 Ci/mmol; Amersham Corp.)  to a 
specific activity of >2  x  l0  s cpm/mg. 
Northern Hybridization.  20  x  los adherent macrophages were 
stimulated with medium only, IFN-'y only, or IFN-3' with TGF-/3 
(5 ng/rnl).  In some experiments, the cells were stimulated with 
IFN-3, for 18 h before being treated with TGF-B. Total KNA was 
isolated by a modification of the rapid guanidininm isothiocyanate 
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kit (Promega, Madison, WI) and quantitated using the DNA Dip- 
stick kit (Invitrogen,  San Diego,  CA). Equal amounts  of RNA 
were denatured in formamide (50%), formaldehyde (6.5%) sample 
buffer (65~  15 rain), run on formaldehyde (1.8%), agarose (0.8%) 
gels,  and  transferred  to  reinforced  nitrocellulose  membranes 
(Duralose-UV; Stratagene) using a positive pressure transfer ap- 
paratus (Posiblot; Stratagene) according to the manufacturer's pro- 
tocol. The membranes were Lrv crosslinked, prehybridized for 3-4 h 
at 65~  in 6x  SSPE (0.9 M NaC1, 60 mM sodium-phosphate, 
3 mM EDTA, pH 7.4; 5 x Denhardt's; 1% SDS; 100 #g/ml salmon 
sperm DNA), and hybridized with respective probes (see figure 
legends) for 16-24 h. After hybridization  the filters were washed 
in 2x  SSC, 0.1% SDS for 30 min at room temperature, followed 
by two washes (15 rain each) in 6x  SSC, 0.1% SDS at 65~  (lx 
SSC  =  0.15 M NaC1, 0.015 M sodium citrate, pH 7.0) and one 
wash (5 rain) in 2x SSC, 0.1% SDS at 37~  and exposed to auto- 
radiography film. For reprobing,  the filters were stripped of the 
oligonucleotide probe by two washes (15 min) in boiling elution 
buffer (0.05x  SSC, 0.01 M EDTA, pH 8.0, 0.1% SDS), checked 
for complete removal of the probe by autoradiography, and rehy- 
bridized. 
Nuclear Run-On Analysis.  Nuclei were prepared from macro- 
phage monolayers (20--40 x  10  e cells) as described (28). For in 
vitro transcription,  freshly thawed nuclei were incubated in tran- 
scription buffer (150 mM KC1, 10 mM Tris, pH 8, 5 mM MgC12, 
0.5 mM ribonucleotide  (adenosine, cytosine, guanosine) triphos- 
phate, 5 mM DTT, 0.05 U/ml RNaseBlock II [Stratagene], 200 mCi 
ot-[3zP]UTP [800 mCi/mmol;  Amersham Corp.])  for 30 rain at 
30"C. The reaction was stopped by addition of 40 U RNase-free 
DNase I (2.2  x  106 U/rag; Stratagene). Elongated labeled tran- 
scripts were isolated by the method of Chomczynski  and Sacchi 
(32), repeatedly precipitated with isopropanol, dissolved  in 1% SDS, 
and counted. Equal amounts of [32p]RNA probes were hybridized 
to an iNOS-spedfic  cDNA fragment  or to a fragment  of mouse 
/~-actin cDNA  (see figure  legends)  that  had  been  slot-blotted 
(Minifold II slot-blotter; Schleicher & Schuell, Inc.) and UV cross- 
linked onto nitrocellulose (200 ng/slot).  Prehybridization  (16 h, 
65"C) and hybridization (48 h, 65"C) were performed in the same 
solution as for Northern blots. Posthybridization washes consisted 
of2x SSC, 0.1% SDS (30 min, 25"C), 6x SSC, 0.1% SDS (twice 
for 20 min, 650C), 2x  SSC (30 rain, 25~  2x  SSC, 10 mg/ml 
RNAse A (30 rain, 37~  2x  SSC, 0.1% SDS (15 rain, 65~ 
The extent of hybridization  to each slot was quantified by video- 
densitometry. 
mRNA Stat~litr Analrs~  Ma=ophag~  monohy~ were s~u- 
lated  with IFN-3' (20 ng/ml) in the presence or absence of TGF-/3 
(5 ng/ml) for 5 or 13 h.  Actinomycin D  (5 #g/ml) was added. 
Total RNA was prepared at the indicated time points and further 
processed for Northern hybridization  as described above. 
Results 
Suppression of NO Release by TGF-~ Is Due to Suppression 
ofiNOS Enzyme Activity.  In the course of the studies de- 
scribed below, we observed a mean suppression of NO re- 
lease by TGF-/8 from IFN-3,-stimulated macrophages of 90.8 
_+  0.4%  at TGF-B concentrations  of I>1 ng/ml  (mean  _+ 
SEM of 49 experiments),  with 0.14  _+  0.05 ng/ml  (5.6  _+ 
2 pM, 7 experiments) causing 50% inhibition,  confirming 
the original  observations (16). 
Suppression of NO release by TGF-B could be due to a 
direct effect on iNOS, or instead,  could reflect a decreased 
ability of the cells to take up t-arginine,  provide NADPH, 
recycle oxidized biopterin, or preserve NO from other reac- 
tions before its encounter with dissolved 02 and conversion 
to  NOz-.  To discriminate  between these possibilities,  we 
carried out enzyme activity assays on cell sonicates in the pres- 
ence of optimal concentrations of t-arginine, NADPH, FAD, 
dithiothreitol,  and tetrahydrobiopterin (23). As seen in Table 
1, the activity of iNOS under these conditions was suppressed 
97-100%  when macrophages were treated with TGF-B. 
TGF-~ Blocks the Induction of  iNOS Protein.  The reduced 
activity of iNOS reflected a decrease of iNOS protein as re- 
vealed by immunoblot with a monospecific rabbit anti-iNOS 
antibody (26) (Fig.  1 A). No iNOS was detected in unstimu- 
lated macrophages after 14, 24, or 48 h of incubation (lanes 
NS). Upon stimulation with IFN-% iNOS was induced in 
increasing amounts from 14 to 48 h (lanes/). TGF-/~ blocked 
this induction  (lanes 1+7). 
Endothelial cNOS (33) as well as mouse macrophage iNOS 
(34, 35) have been found in a particulate as well as a soluble 
fraction of cell lysates,  The total absence of immunoreactive 
iNOS in lysates from TGF-/~-treated  cells suggested that both 
components were suppressed. This was confirmed by separately 
immunoblotting whole lysates (lanes L) as well as the cyto- 
solic (lanes C) and the particulate (lanes P) fractions of whole 
lysates (Fig.  1 B). 
TGF-~ Treatment  Reduces iNOS mRNA Levels.  As shown 
in Fig. 2, IFN-3' induced iNOS mRNA (lanes/) within 4 h 
of treatment, with the signal persisting through 72 h. TGF-B, 
added at the same time as IFN-3, (lanes I+T), did not reduce 
the level ofiNOS mKNA at 4 h, but caused a marked reduc- 
tion of iNOS mKNA by 24 h.  The complete suppression 
of iNOS induction seen at the protein level could therefore 
be explained partially, but not entirely, by the late decrease 
in iNOS mKNA. 
TGF-~ Does Not Affect iNOS Gene Transcription.  As shown 
Table  1.  Effect  of TGF-B on IFN-y-induced iNOS 
Enzyme Activity 
Exp.  IFN-3,  TGF-fl  Specific  activity  Suppression 
pmol/mg protein per rain  % 
-  -  0  N/A 
+  -  380  0 
+  +  10  97.4 
-  -  0  N/A 
+  -  400  0 
+  +  0  100 
12 x  106 thioglycollate  broth-elicited mouse peritoneal cells were seeded 
in 100-mm tissue culture dishes, washed, and incubated with medium 
or TGF-B (2.5 ng/ml) for 0 (Exp. 1) or 16 h (Exp. 2) and then stimulat- 
ed with IFN-3' (20 ng/ml). NOS enzyme activity  was assayed  48 h later. 
The two experiments are representative of eight. N/A, not applicable. 
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dependent manner in both soluble and particulate com- 
partments.  Thioglycolhte  bmth-dicited mouse peritoneal 
cells were treated as follows. (A) Either no stimulus (lanes 
NS), 20 ng/ml IFN-~/ (lanes /), or 20 ng/ml IFN-'y + 
10 ng/ml TGF-B (lanes I+T) were added and the phtes 
incubated for the periods of time indicated above the lanes 
before being lysed by sonication and subjected  to SDS- 
PAGE followed by Western blot with anti-iNOS IgG. (B) 
Either no stimulus (lanes N$) or TGF-B at the indicated 
final concentrations (ng/ml)  +  IFN-3, (20 ng/ml) was 
added. The cells were incubated for 48 h before being lysed 
(lanes L), separated into cytosolic (lanes C) and particu- 
late (lanes P) fractions,  and subjected to SDS-PAGE fol- 
lowed by Western blot with anti-iNOS IgG. Relative mo- 
lecular masses of prestained markers are shown at the left 
(x103).  Arrows  indicate  the  specific  iNOS  doublet 
(,,,130,000  Mr). 
in Fig.  3,  the level of transcription of iNOS was equal in 
macrophages stimulated with IFN-3, alone (lane/) or in com- 
bination with TGF-B (lane I+T). Transcription was also de- 
tected in unstimulated macrophages (lane NS). The results 
from three such nuclear run-on experiments were quantitated 
by videodensitometry.  Setting the ratio of iNOS peak area~B- 
actin peak area to 1 for unstimulated macrophages, the ratio 
of iNOS//~-actin was 0.57  _+ 0.25 and 0.56  _+ 0.09 (mean 
+_ SD) for the IFN-3, and the IFN-y  +  TGF-~ stimulation 
conditions, respectively, indicating that TGF-B did not affect 
iNOS gene transcription. Results were similar  at 3.5 h of 
stimulation (Fig.  3)  and at 24 h  (data  not shown). 
Figure  2.  Exposure to TGF-~ decreases iNOS mRNA. Macrophages 
were stimulated with 20 ng/ml IFN-3' alone (lanes/) or in combination 
with 5 ng/ml TGF-/~ (lanes I+T) for 4,  24,  48, or 72 h. The mRNA 
from each sample was blotted and hybridized with a DNA probe for iNOS, 
prepared from an EcoRI-AccI fragment of cDNA done B2 (26). As a con- 
trol, the blot was hybridized simultaneously with an oligonucleotide  probe 
for B-actin (Clontech).  The apparent increase in the ~-actin region in lanes 
I  reflects spillover from the iNOS band. 
Figure  3.  TGF-B treatment does not diminish iNOS gene transcrip- 
tion. Macrophages  were unstimulated (lane NS) or stimulated with 20 
ng/ml IFN-~/alone (lane/) or in combination with 5 ng/ml TGF-B (lane 
I+T) for 3.5 h. The rate of transcription of iNOS or of B-actin by isolated 
nuclei was determined by slot-blotting the elongated, labeled RNA tran- 
scripts and hybridizing them to the indicated gene fragments for autoradi- 
ography. The iNOS gene fragment was the same as in Fig. 2. The ~-actin 
fragment was a 749-bp EcoRI fragnl-.ent  of phagemid pBluescript SK(+) 
containing the mouse 3-actin cDNA. This result is representative of three 
experiments. 
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phages were  stimulated  with 20 ng/ml  IFN-'y  alone  (lanes/)  or in combi- 
nation 5 ng/ml  with  TGF-B  (lanes  I+T) for 5 (A) or 13 h (B). Actinomycin 
D (5/~g/ml) was added  for 0, 45, or 90 (A) or for 0, 15, 30, 60, or 120 
min (B). mRNA  was prepared  for Northern  blot with an iNOS-specific 
probe (see  Fig. 2). As a control, the blot was hybridized  simultaneously 
with a probe for ~-actin (see Fig. 2). In A, the blot was stripped and 
reprobed with a probe for GAPDH as an additional control. 
TGF-B Treatment  Reduces iNOS raRNA Stability.  The fore- 
going results suggested that TGF-/3 treatment is likely to re- 
duce iNOS  mRNA  stability.  This  possibility  was  tested 
through the use of the transcription inhibitor actinomycin 
D  in two settings.  In the first instance, macrophages were 
stimulated with IFN-3r in the presence or absence of TGF-~ 
for 5 h. This time point was chosen so that the levels ofiNOS 
mRNA would be identical in the TGF-~-treated macrophages 
(Fig. 4, lanes I+T) and in macrophages treated with IFN-3~ 
alone (Fig. 4, lanes I; see also Fig. 2). Upon addition of ac- 
tinomycin D, iNOS mRNA decreased faster in the TGF-~- 
treated macrophages than in the untreated cells (Fig. 4 A). 
In the second instance, macrophages were stimulated  with 
IFN-3, in the presence or absence of TGF-B for 13 h (Fig. 
4 B). This time point was chosen so that the level of iNOS 
mRNA in the TGF-~-treated macrophages (lanes I+T) was 
already greatly reduced compared to the level  of  iNOS mRNA 
in the cells treated with IFN-~/alone (lanes/). Strikingly, 
iNOS mRNA was now much more stable than at 5 h, and 
TGF-B  no longer accelerated its degradation. 
TGF-fl  also Acts at  the  Translational and Posttranslational 
Leve/s.  Above,  we showed that TGF-fl reduced partially the 
level of iNOS mRNA (Fig. 2), while at the protein level the 
reduction of iNOS protein appeared complete (Fig. 1). This 
discrepancy suggested  that TGF-fl might also affect iNOS 
at the translational and/or posttranslational  levels. Thus, we 
reexamined the notion that iNOS is no longer suppressible 
by TGF-fl after iNOS is expressed (16). In the experiment 
shown in Fig. 5 A, macrophages were stimulated with IFN-3, 
for a total of 48 h. TGF-~ or medium was added at 0,  3, 
9, or 24 h after addition of IFN-3,.  Cells to which TGF-B 
was added at 0, 3, 9, and even 24 h after IFN-qr contained 
little or no iNOS protein at 48 h, even though iNOS had 
already been well expressed by 24 h after exposure to IFN-~/ 
(Fig. 1 A). Alternatively, macrophages were stimulated  for 
24 h with IFN~, at which time medium or TGF-~ was added. 
Lysates were made at 0, 2, 6,  16, or 20 h after addition of 
medium or TGF-B. By 16 and 20 h of  incubation with TGF-~, 
preexistent  iNOS protein had been reduced.  The apparent 
discrepancy with previous results (16) was explained by the 
observation that by 24-36 h after IFN-'y treatment, NO2- 
accumulation was maximal in the supernatants  of cultured 
macrophages  and did not further increase by 48 h (Fig.  5 
C). This reflects factor accumulation in and/or depletion from 
the conditioned medium, since iNOS activity can be revived 
in non-TGF-B-treated cells by giving the cells fresh medium 
(Vodovotz, V., N. S. Kwon, C. Bogdan, J. Paik, Q.-w. Xie, 
and C.  Nathan, manuscript in preparation). 
After iNOS is expressed, reduction in iNOS protein by 
TGF-~ out of proportion to the reduction in mRNA could 
be due to a decrease in iNOS mR.NA translation  and/or to 
enhanced degradation of iNOS protein.  To test the first pos- 
sibility, macrophages were stimulated for 17 h with IFN-% 
at which time they were incubated either with medium or 
with TGF-~ for further periods. The macrophages were then 
pulsed with [3sS]t-cysteine for 30 min to label newly syn- 
thesized iNOS as detected in immunoprecipitates with anti- 
iNOS  antiserum.  No  iNOS  was  immunoprecipitated by 
preimmune antiserum (data not shown). As seen in Fig. 6 
A, no translation of  iNOS was detected in unstimulated mac- 
rophages (lane NS). The rate of synthesis of iNOS was in- 
distinguishable  in medium- (lanes M) or TGF-~- (lanes T) 
treated cells up to 4 h of treatment. Thereafter, progressively 
less iNOS synthesis  was sustained in TGF-B-treated cells; none 
could be detected by 8 h. As shown in Fig. 6 B, this effect 
could not be attributed to reduction of  iNOS mRNA. Thus, 
when TGF-B was added 17 h after IFN-% the further ac- 
cumulation of iNOS mRNA over the subsequent 24 h was 
blocked, but the level of mRNA that had been present  at 
17 h was only minimally reduced, consistent with the result 
in Fig. 4 B.  We conclude that the results in Fig. 6 A  are 
attributable  primarily  to  decreased  translation  of iNOS 
mRNA. 
We next examined whether TGF-~ could also increase 
degradation of iNOS protein.  Macrophages were stimulated 
for 18 h with IFN-3,,  at which time they were incubated 
either with medium or with TGF-~,  pulsed  with [3sS]t- 
cysteine, and chased  with an excess  of  nonradioactive  t-cysteine. 
Immunoprecipitation with anti-iNOS antiserum was then 
carried out in order to examine the fate of iNOS (Fig. 6 C). 
By the end of the pulse period (a total of 4 h with TGF-fl) 
the same amount of  iNOS protein had been synthesized both 
by the medium-treated (lanes  M) and the TGF-fl-treated (lanes 
T) macrophages. However, during the chase period, the rate 
of degradation  of labeled iNOS protein was greater in the 
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Figure 5.  TGF-3  treatment  reduces  iNOS protein  when  added  late  after 
iNOS induction.  (A) Macrophages  were stimulated  with 20 ng/ml IFN-3, 
(lanes/), followed  by 2.5 ng/ml TGF-fl (lanes T) 0, 3, 9, and 24 h later 
as indicated  above  the lanes. Lysates  were subjected  to SDS-PAGE  followed 
by Western  blot with anti-iNOS IgG. (B) Macrophages  were stimulated 
with 20 ng/ml IFN-% 24 h later, either  medium  (lanes  M) or 2.5 ng/ml 
TGF-fl (lanes T) was added; 0, 2, 6, 16, or 20 h later (as indicated  above 
the lanes) lysates  were subjected  to SDS-PAGE followed  by Western  blot 
with anti-iNOS IgG. Relative  molecular  masses  of prestained  markers are 
shown on the left (xl03) and arrows indicate  the specific  iNOS doublet 
(~D0,000 Mr). The experimental  design  is pictured  below each blot. (C) 
NO2- released  into the medium by the cells from the experiment de- 
scribed in B. Results are representative of three experiments. 
TGF-/5-treated  cells (compare lanes M vs. lanes  T  at 8 h of 
chase  and beyond). 
Discussion 
The suppression of iNOS expression is probably as impor- 
tant to its regulation as its induction. We have focused on 
the regulation of iNOS expression in macrophages by TGF-3 
because macrophages use NO to restrict the growth of tumor 
cells and pathogens; TGF-3 is produced by many tumors (36) 
and induced by certain NO-sensitive pathogens (37),  and 
TGF-3 is produced by activated T cells and macrophages them- 
selves (38,  39). 
The complex biochemistry of  NO production affords many 
potential sites for regulatory action. TGF-B might cause diver- 
sion of detectable NO  away from NO2-,  e.g.,  to  nitro- 
sothiols (40). TGF-/3 might act by limiting the availability 
or activity of cosubstrates, cofactors,  prosthetic groups, or 
accessory  proteins  necessary  for NO  production,  such  as 
t-arginine, NADPH, glutathione, tetrahydrobiopterin, FAD, 
ravin mononucleotide, heme, calmodulin, and dihydropteri- 
dine reductase.  In smooth muscle cells, for example,  tetra- 
hydrobiopterin availability appears to be a rate-limiting step 
in the induction of iNOS-like activity (41). Finally, TGF-B 
might induce the production ofiNOS inhibitors, such as the 
N6,NG-dimethylarginine recently identified in human urine 
and plasma (42).  While an effect of TGF-B on such factors 
was not excluded, the main action of TGF-/3 was to decrease 
the amount of iNOS protein in the cells through potentially 
synergistic action at three different levels: enhanced degrada- 
610  Suppression  of Nitric Oxide Release by Transforming  Growth Factor/~ Figure 6.  Late  addition of TGF-/3 to already activated macrophages 
decreases  translation of iNOS mRNA and increases  degradation of  iNOS 
protein. (A) Macrophages  were  unstimulated (lanes  NS) or stimuhted with 
20 ng/ml IFN-3' (hnes M and 7) for 17 h. Medium  or 2.5 ng/ml TGF-/3 
was then added for 0, 2, 4, 6, or 8 h, after which the cells were pulsed 
with [3sS]t-cysteine  for 30 min. The cells were  lysed, immunoprecipitated 
with anti-iNOS antiserum, and subjected  to SDS-PAGE  and autoradiog- 
raphy. (/3) As a control  for A, macrophages  were  either unstimulated (lane 
NS) or stimulated with 20 ng/ml IFN-3, alone (lane/) for 18 h. Medium 
(lanes M) or 5 ng/ml TGF-/3 (lanes 7) was added for 3, 11, or 24 h and 
then mR2qA  blotted and hybridized  with DNA probes  SlX'cific  for iNOS 
(see Fig. 2) and for GAPDH  (as control). (C) Macrophages  were  unstimu- 
lated (lane NS) or stimulated with 20 ng/ml IFN-3' (lanes M and T) for 
18 h. Medium or "I"GF-/3 was added for 45 rain, the cells pulsed with 
[3ss]t-cysteine  for 3 h, and then chased for a further 56 h. The cells were 
harvested at various times during the chase, lysates  were immunoprecipi- 
rated with anti-iNOS antiserum, and subjected  to SDS-PAGE  and autora- 
diography. Numbers on the left side of each autoradiogram indicate the 
apparent relative molecular masses (x 103) of prestained markers, and the 
horizontal arrow indicates the specific iNOS doublet ('~130,000 Mr). 
tion ofiNOS mRNA and its impaired translation combined 
with  acceleration  of iNOS protein  degradation. 
The little that is known regarding the mechanisms of con- 
trol of protein expression by TGF-/3 in other systems points 
to no single regulatory theme (36).  In hepatocytes, TGF-B 
treatment  reduces  the  levels  of hepatocyte  growth  factor 
mRNA  (43),  and  in  melanoma  cell  lines  and  blood 
mononuclear cells,  TGF-/3 treatment  reduces MHC class II 
mRNA  (44).  In  macrophages,  TGF-B  suppresses  TNF-ot 
production by reducing TNF-c~ mRNA translation (28), and 
the same mechanism underlies TGF-/5-mediated suppression 
of the synthesis of milk caseins by hctogenic hormone-treated, 
pregnant  mice (45).  In human peripheral blood T  lympho- 
cytes, TGF-/3 blocks secretion of bioactive IL-1 while para- 
doxicaUy increasing IL-1 mRNA (46). The foregoing effects 
of TGF-/3 each appear to be limited to one regulatory mecha- 
nism, in contrast to the multiple levels at which TGF-B affects 
iNOS. 
No iNOS transcription was detected in unstimulated RAW 
264.7 cells (26), and no accumulation of iNOS mRNA was 
detected in unstimulated, thioglycollate-elidted primary mac- 
rophages (Fig.  6 B).  Thus,  it was a surprise to find a low 
level of transcription  of  iNOS in primary macrophages without 
addition of IFN-3/(Fig. 3). This probably reflects a response 
to the thioglycollate broth used to inflame the peritoneum 
and dicit the cells. Since IFN-'y as a single stimulus appears 
to increase iNOS mRNA not by enhancing iNOS gene tran- 
scription  (Fig.  3),  it presumably suppresses iNOS mRNA 
degradation. In contrast, the synergistic combination of IFN-3' 
and LPS markedly enhances iNOS transcription both in RAW 
264.7 cells (26) and in thioglycollate broth-elicited macro- 
phages (data not shown). TGF-/3 appears powerless to diminish 
iNOS transcription;  rather, it reduces iNOS expression post- 
transcriptionally.  This may explain why TGF-/3 suppresses 
iNOS  expression  so effectively when  iNOS  is induced by 
IFN-~, alone, but so weakly when iNOS is induced by IFN-3' 
and LPS (16). 
TGF-/3 has been implicated in diverse processes such as em- 
bryological  development  (36).  In  transgenic  mice  whose 
TGF-/31  gene had been knocked out,  the main defect was 
lethal, multifocal inflammatory disease (47, 48). It would ap- 
pear from these studies that the nonimmunological roles of 
TGF-13 can be filled by other  factors,  while TGF-13's  im- 
munosuppressive role appears to be unique.  The regulatory 
actions of TGF-B on iNOS may be critical for controlling 
inflammation. 
We thank M. Prystowsky and A. Orlofsky (University of Pennsylvania, Philadelphia, PA) for their gift 
of/3-actin cDNA, and M.  Narachi  (Amgen,  Thousand  Oaks,  CA) for his gift of TGF-B1. 
This work was supported by National Institutes  of Health grant  CA-43610 to C. Nathan, and Deutsche 
Forschungsgemeinschaft  grant  Bo 996/1-1  to C. Bogdan. 
611  Vodovotz  et al. Address correspondence to Cad Nathan, Division of Hematology-Oncology, Department of Medicine, 
Box 57, Cornell University Medical College, 1300 York Avenue, New York, NY 10021. 
Received for publication  2 March  1993. 
~fereBces 
1.  Nathan, C. 1992. Nitric oxide as a secretory product of mam- 
malian cells. FASEB (Fed. Am. Soa Ex  F  Biol.) J. 6:3051. 
2.  Hibbs, J.B., Jr., R.R. Taintor, Z. Vavrin, D.L. Granger, J-C. 
Drapier, I.J. Amber, and J.R. Lancaster,  Jr. 1990. Synthesis 
of nitric oxide from a terminal guanidino nitrogen atom of 
L-arginine: a molecular mechanism regulating cellular  prolifer- 
ation  that targets intracellular iron. In  Nitric  Oxide from 
bArginine:  A Bioregulatory System. S. Moncada and E.A. 
Higgs, editors. Elsevier Science Publishers B.V., Amsterdam. 
189-223. 
3.  Stuehr, D.J., and M.A. Marietta. 1985. Mammalian nitrate 
biosynthesis: mouse macrophages produce nitrite and nitrate 
in response to Esche~chia coli lipopolysaccharide.  Proc Natl. Acad. 
Sci. USA.  82:7738. 
4.  Amber, I.J., J.B. Hibbs, Jr., lk.R. Taintor, and Z. Vavrin. 1988. 
The barginine dependent effector  mechanism  is induced  in mu- 
fine adenocarcinoma cells by culture supernatant from cyto- 
toxic activated macrophages.  J. Leukocyte Biol. 43:187. 
5.  Curran,  R.D., T.R. Billiar, D.J. Stuehr, K. Hoffmann, and 
R.L. Simmons. 1989. Hepatocytes produce nitrogen oxides 
from L-arginine  in response to inflammatory  products of  Kupffer 
ceils. J. Ex  F  Ailed. 170:1769. 
6.  Nussler, A.K., M. Di Silvio, T.IL.  BiUiar, R.A. Hoffman, D.A. 
Geller, R. Selby,  J. Madariage, and R.L. Simmons. 1992. Stim- 
ulation of the nitric oxide synthase pathway in human hepato- 
cytes by cytokines and endotoxin. J. Ex  F  Med. 176:261. 
7.  Marsden, P.A., and B.J. Balhrmann.  1990. Tumor necrosis 
factor o~ activates  a soluble guanylate cydase in bovine glomer- 
ular mesangial cells via an L-arginine-dependent  mechanism. 
J. Extx  Med. 172:1843. 
8.  Gross, S.S., E.A. Jaffe, R. Levi, and tL.G. Kilbourn.  1991. 
Cytokine-activated endothelial cells express an isotype of ni- 
tric oxide synthase which is tetrabydrobiopterin-dependent, 
calmodulin-independent  and inhibited  by arginine analogs  with 
a rank-order  of potency  characteristic  of activated  macrophages. 
Biochem. Biophys. Res. Commun.  178:823. 
9.  Busse,  R., and A. Miilsch. 1990. Induction of  nitric oxide syn- 
thase by cytokines in vascular smooth muscle cells. FEBS (Fed. 
Eur. Biochem. Sci.) Let.  275:87. 
10.  Schulz, R., E. Nava, and S. Moncada. 1992. Induction and 
potential biological relevance of a Ca2+-independent nitric 
oxide synthase in the myocardinm. Br. j. Pharmacol. 105:575. 
11.  Roberts, A.B., Y. Vodovotz,  N.S. Roche, M.B. Sporn, and C.F. 
Nathan.  1992. Role of nitric oxide in antagonistic effects of 
transforming  growth factor-B  and interleukin-lB  on the beating 
rate of cultured cardiac myocytes. Mol. Endocrinol. 6:1921. 
12. Brady, A.J.B., P.A. poole-Wilson, S.E. Harding,  and J.B. 
Warren. 1992. Nitric oxide production within cardiac myo- 
cytes reduces their contractility in endotoxemia.  Am.J. Physiol. 
(Heart Circ. Physiol.). 263:H1963. 
13.  Galea, E., D.L. Feinstein, and D.J. Reis. 1992. Induction of 
calcium-independent  nitric oxide synthase activity in primary 
rat glial cultures. Pro~ Natl.  Acad. Sci. USA.  89:10945. 
14.  Simmons,  M.L., and S. Murphy. 1992. Induction of  nitric oxide 
synthase in glial cells.  J. Neurochem. 59:897. 
15.  Heck, D.E., D.L. Laskin,  C.K. Gardner, andJ.D. Laskin. 1992. 
Epidermal growth factor suppresses nitric oxide and hydrogen 
peroxide production by keratinocytes: Potential role for nitric 
oxide in the regulation of wound healing.  J. Biol. Chem. 267: 
21277. 
16. Ding, A., C.F. Nathan, J. Graycar, K. Derynck, D.J. Stuehr, 
and S. Srimal. 1990. Macrophage  deactivating  factor and trans- 
forming growth factors-/~l, -B2, and -B3 inhibit induction of 
macrophage nitrogen oxide synthesis by IFN-% J. Immunol. 
145:940. 
17.  Nelson, B.J., P. Ralph, S.J. Green, and C.A. Nacy. 1991. Dif- 
ferential susceptibility  of  activated  macrophage  cytotoxic  effector 
reactions to the suppressive effects of transforming growth 
factor-/~l, j. Immunol.  146:1849. 
18.  Pfeilsehifrer,  J., and K. Vosbeck. 1991. Transforming growth 
factor/3z inhibits interleukin 1/~- and turnout necrosis factor 
c~-indnction  of nitric oxide synthase  in rat renal mesangial  cells. 
Biochem. Biophys. Res. Commun.  175:372. 
19.  Schini, V.B., W. Durante, E. Elizondo, T. Scott-Burden, D.C. 
Junquero, A.I. Schafer,  and P.M. Vanhoutte. 1992. The induc- 
tion of nitric oxide synthase activity is inhibited by TGF-/31, 
PDGF^B and PDGFBB in vascular smooth muscle cells. Eur. 
J. Pharmacol. 216:379. 
20. Junquero, D.C., T. Scott-Burden, V.B. Schini, and P.M. Van- 
houtte.  1992. Inhibition  of cytokine-induced nitric  oxide 
production  by transforming  growth factor-/31  in human smooth 
muscle cells.  J. Physiol (Lond.). 454:451. 
21.  McCall, T.B., R.M.J. Palmer, and S. Moncada. 1992. Inter- 
leukin-8 inhibits the induction of nitric oxide synthase in rat 
peritoneal neutrophils. Biochem. Biophys. Res. Commun. 186:680. 
22.  Liew,  F.Y., Y. Li, A. Severn, S. Millott, J. Schmidt, M. Salter, 
and S. Moncada. 1991. A possible novel pathway of regulation 
by murine T helper type-2 (Th2) of a Thl cell activity via the 
modulation of the induction of nitric oxide synthase on mac- 
rophages. Eur. J. Immunol.  21:2489. 
23.  Stuehr, D.J., H.J. Cho, N.S. Kwon, M.F. Weise, and C.F. Na- 
than, 1991. Purification and characterization of the cytokine- 
induced macrophage  nitric oxide synthase:  an FAD- and FMN- 
containing flavoprotein. Proa Natl. Acad. Sci. USA. 88:7773. 
24.  Hevel,  J.M.K.A. White, and M.A. Marietta. 1991. Purification 
of the inducible murine macrophage nitric oxide synthase. 
Identification as a flavoprotein.  J. Biol. Chem.  266:22789. 
25. Lyons,  C.tL., G.J. Orloff, and J.M. Cunningham. 1992. Mo- 
lecular cloning and functional expression  of an inducible nitric 
oxide synthase from a routine macrophage cell line. J. Biol. 
Chem.  267:6370. 
26.  Xie, Q.W., H.J.  Cho, J.  Calaycay, R.A.  Mumford, K.M. 
Swiderek, T.D. Lee, A. Ding, T. Troso, and C. Nathan. 1992. 
Cloning and characterization  of inducible  nitric oxide synthase 
from mouse macrophages. Science (Wash. DC).  256:225. 
27. Lowenstein,  C.J.C.S. Glatt, D.S. Bredt, and S.H. Snyder. 1992. 
Cloned and expressed macrophage nitric oxide synthase con- 
trasts with the brain enzyme. Proc. Natl.  Acad. Sci. USA. 
612  Suppression  of Nitric Oxide Release by Transforming  Growth Factor B 89:6711. 
28.  Bogdan, C., J. Pail Y. Vodovotz, and C. Nathan.  1992. Con- 
trasting mechanisms for suppression of macrophage cytokine 
release by transforming  growth factor-/3 and interleukin-10. 
J. Biol. Chem.  267:23301. 
29.  Pollock, J.S.,  U.  F6rstermann,  J.A. Mitchell,  T.D. Warner, 
H.H.H.W.  Schmidt,  M.  Nakane,  and  F.  Murad.  1991. 
Purification and characterization  of particulate endothelium- 
derived relaxing factor synthase from cultured and native bo- 
vine aortic endothelial cells./boa Natl. AcacL Sci. USA. 88:10480. 
30.  Leemmli, U.K. 1970. Cleavage of structural  proteins during 
the assembly of the head of bacteriophage T4. Nature (Lond.). 
227:680. 
31.  1992. Current Protocols in Molecular Biology. F.M. Ausubel, 
R. Brent,  R.E.  Kingston,  D.D.  Moore, J.G. Seidman, J.A. 
Smith, and K. Struhl, editors. John Wiley & Sons., Inc., New 
York. 
32.  Chomczynski,  P., and N. Sacchi. 1987. Single-step method 
of RNA isolation by acid guanidinium  thiocyanate-phenol- 
chloroform  extraction.  Anal. Biochem.  162:156. 
33.  F6rstermann, U., J.S. Pollock, H.H.H.W. Schmidt, M. Heller, 
and  F.  Murad.  1991. Calmodulin-dependent  endothelium- 
derived relaxing factor/nitric oxide synthase activity is present 
in  the  particulate  and  cytosolic fractions  of bovine  aortic 
endothelial cells. Proc Natl. Acad. Sci. USA.  88:1788. 
34.  Hiki, K., Y. Yui, R. Hattori, H. Eizawa, K. Kosuga, and C. 
Kawai. 1991. Cytosolic and membrane-bound nitric oxide syn- 
thase. Jpn. j. Pharmacol. 56:217. 
35.  P6rstermann,  U., H.H.H.W. Schmidt, K.L. Kohlman, and F. 
Murad. 1992. Induced RAW 264.7 macrophages express soluble 
and particulate nitric oxide synthase: inhibition by transforming 
growth factor-/3. Eur. J. Pharmacol. 225:161. 
36.  Massagu6, J. 1990. The transforming growth factor-/3 family. 
Annu.  Rev. Cell Biol. 6:597. 
37.  Barral-Netto,  M., A. Barral, C.E. Brownell, Y.A.W. Skeiky, 
L.R. Ellingsworth, D.R. Twardzik, and S.G. Reed. 1992. Trans- 
forming growth factor-/3 in leishmanial infection: A parasite 
escape mechanism.  Science (Wash. DC).  257:545. 
38.  Kehrl, J.H., L.M. Wakefield, A.B. Roberts,  S. Jakowlew, M. 
Alvarez-Mon, R. Derynck, M.B. Sporn, and A.S. Fauci. 1986. 
Production of transforming growth factor/3 by human T lym- 
phocytes and its potential role in the regulation ofT cell growth. 
j.  Exp. Med.  163:1037. 
39.  Assoian, R.K., B.E. Fleurdelys, H.C. Stevenson, P.J. Miller, 
D.K. Madtes, E.W. Raines, R. Ross, and M.B. Sporn. 1987. 
Expression and secretion of type/3 transforming growth factor 
by activated human macrophages. Proc Natl. Acad. Sci. USA. 
84:6020. 
40.  Stamler, J.S., D.J. Singel, andJ. Loscalzo. 1992. Biochemistry 
of nitric oxide and its redox-activated  forms. Science (Wash. DC). 
258:1898. 
41.  Gross, S.S., and R. Levi. 1992. Tetrahydrobiopterin synthesis: 
an absolute requirement for cytokine-induced  nitric oxide gener- 
ation by vascular smooth muscle. J. Biol. Chem.  267:25722. 
42.  Vallance, P., A. Leone, A. Calver, J. Collier, and S. Moncada. 
1992. Endogenous dimethylarginine  as an inhibitor  of nitric 
oxide synthesis. J.  Cardiovas~ Pharmacol. 20(Suppl.  12):60. 
43.  Matsumoto,  K., H. Tajima, H. Okazaki,  and T. Nakamura. 
1992. Negative regulation  of hepatocyte growth factor gene 
expression in human lung fibroblasts  and leukemic cells  by trans- 
forming growth factor-/31 and glucocorticoids. J. Biol. Chem. 
267:24917. 
44.  Czarniecki, C.W., H.H. Chiu, G.H.W. Wong, S.M. McBabe, 
and  M.A.  Palladino. 1988. Transforming  growth factor-/31 
modulates the expression of class II histocompatibility antigens 
on human  cells. J. Immunol.  140:4217. 
45.  Robinson, S.D., A.B. Roberts, and C.W. Daniel. 1993. TGF/3 
suppresses casein synthesis in mouse mammary explants and 
may play a role in controlling  milk levels during  pregnancy. 
J.  Cell Biol. 120:245. 
46.  Chantry,  D., M. Turner, E. Abney, and M. Feldmann. 1989. 
Modulation  of cytokine production  by transforming  growth 
factor-/3. J. Immunol.  142:4295. 
47.  Shull, M.M., I. Ormsby, A.B. Kier, S. Pawlowski, R.J. Die- 
bold, M. Yin, R. Allen, C. Sidman, G. Proetzel, D. Calvin, 
N. Annunziata,  and T. Doetschman.  1992. Targeted disrup- 
tion of the mouse transforming growth factor-/31 gene results 
in multifocal inflammatory  disease. Nature (land.).  359:693. 
48.  Kulkarni, A.B., C.-G. Huh, D. Becket, A. Geiser, M. Lyght, 
K.C. Flanders, A.B. Roberts, M.B. Sporn, J.M. Ward, and S. 
Karlsson. 1993. Transforming growth factor/31 null mutation 
in mice causes excessive  inflammatory response and early death. 
Proa Natl. Acad. Sci. USA.  90:770. 
613  Vodovotz  et al. 